Table 1 MEP amplitudes and stimulation intensity before and after varenicline administration.

From: Compromised neuroplasticity in cigarette smokers under nicotine withdrawal is restituted by the nicotinic α4β2-receptor partial agonist varenicline

Stimulation

TMS Parameter

Medication condition

Baseline 1

Baseline 2

Baseline 3

Cathodal tDCS

MEP

0.3 mg

0.97 ± 0.13

1.01 ± 0.19

0.93 ± 0.13

1.0 mg

0.94 ± 0.11

0.81 ± 0.13

0.92 ± 0.06

Placebo

0.97 ± 0.13

1.06 ± 0.45

0.97 ± 0.12

%MSO

0.3 mg

57.17 ± 14.48

57.08 ± 14.57

1.0 mg

56.08 ± 14.15

56.67 ± 14.06

Placebo

56.50 ± 13.57

56.75 ± 14.07

Anodal tDCS

MEP

0.3 mg

0.95 ± 0.08

0.95 ± 0.13

1.00 ± 0.11

1.0 mg

0.99 ± 0.16

0.88 ± 0.15

0.93 ± 0.13

Placebo

1.00 ± 0.13

0.97 ± 0.15

0.99 ± 0.13

%MSO

0.3 mg

56.83 ± 13.11

57.25 ± 13.07

1.0 mg

57.08 ± 14.37

57.83 ± 14.83

Placebo

56.75 ± 14.00

57.17 ± 13.82

PAS10

MEP

0.3 mg

0.94 ± 0.10

1.05 ± 0.40

1.04 ± 0.15

1.0 mg

0.99 ± 0.10

0.86 ± 0.12

0.90 ± 0.08

Placebo

1.01 ± 0.14

0.93 ± 0.18

0.97 ± 0.10

%MSO

0.3 mg

57.08 ± 11.22

57.17 ± 11.63

1.0 mg

57.75 ± 11.95

58.25 ± 11.93

Placebo

56.67 ± 12.35

57.08 ± 12.38

PAS25

MEP

0.3 mg

0.92 ± 0.11

0.91 ± 0.21

0.95 ± 0.12

1.0 mg

0.97 ± 0.10

0.97 ± 0.19

0.98 ± 0.14

Placebo

1.01 ± 0.10

0.89 ± 0.15

0.94 ± 0.11

%MSO

0.3 mg

56.83 ± 12.34

57.00 ± 12.45

1.0 mg

57.17 ± 11.85

57.58 ± 11.95

Placebo

57.25 ± 11.42

57.58 ± 11.42

  1. Shown are the mean MEP amplitudes ± S.D. and stimulation intensity (percentage of maximum stimulator output, %MSO) means ± S.D. of baselines 1, 2 and 3. The intensity of TMS was adjusted to elicit MEPs with peak-to-peak amplitude of ~1 mV (baseline 1). A second baseline (baseline 2) was recorded three hours after varenicline or placebo intake to determine the impact of the drug on cortical excitability and adjusted if necessary (baseline 3). RM-ANOVAs revealed no significant differences between %MSO values and MEP amplitudes.
Back to article page